Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorBasic Materials
SymbolOTCMKTS:NVZMY
CUSIPN/A
Phone45-4446-0000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.29
Quick Ratio0.77
Price-To-Earnings
Trailing P/E Ratio32.76
Forward P/E Ratio29.77
P/E Growth2.37
Sales & Book Value
Annual Sales$2.21 billion
Price / Sales5.74
Cash Flow$1.8921 per share
Price / Cash27.53
Book Value$6.81 per share
Price / Book7.65
Profitability
EPS (Most Recent Fiscal Year)$1.59
Net Income$473.62 million
Net Margins22.08%
Return on Equity29.76%
Return on Assets17.47%
Miscellaneous
Employees6,441
Outstanding Shares243,260,000
Market Cap$12,622.55
NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions
What is NOVOZYMES A/S/S's stock symbol?
NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."
How were NOVOZYMES A/S/S's earnings last quarter?
NOVOZYMES A/S/S (OTCMKTS:NVZMY) announced its earnings results on Wednesday, April, 25th. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.01. The biotechnology company earned $580.78 million during the quarter. NOVOZYMES A/S/S had a net margin of 22.08% and a return on equity of 29.76%. View NOVOZYMES A/S/S's Earnings History.
When is NOVOZYMES A/S/S's next earnings date?
What price target have analysts set for NVZMY?
2 equities research analysts have issued 12-month price targets for NOVOZYMES A/S/S's stock. Their predictions range from $54.97 to $54.97. On average, they anticipate NOVOZYMES A/S/S's stock price to reach $54.97 in the next twelve months. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Ratings for NOVOZYMES A/S/S.
What is the consensus analysts' recommendation for NOVOZYMES A/S/S?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of NOVOZYMES A/S/S's key competitors?
Some companies that are related to NOVOZYMES A/S/S include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).
Who are NOVOZYMES A/S/S's key executives?
NOVOZYMES A/S/S's management team includes the folowing people:
- Mr. Peder Holk Nielsen, Pres & CEO (Age 62)
- Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 58)
- Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 55)
- Mr. Per Falholt, Consultant (Age 60)
- Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 45)
Has NOVOZYMES A/S/S been receiving favorable news coverage?
Media coverage about NVZMY stock has been trending positive this week, according to Accern. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NOVOZYMES A/S/S earned a news impact score of 0.28 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of NOVOZYMES A/S/S?
Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NOVOZYMES A/S/S's stock price today?
One share of NVZMY stock can currently be purchased for approximately $52.09.
How big of a company is NOVOZYMES A/S/S?
NOVOZYMES A/S/S has a market capitalization of $12.62 billion and generates $2.21 billion in revenue each year. The biotechnology company earns $473.62 million in net income (profit) each year or $1.59 on an earnings per share basis. NOVOZYMES A/S/S employs 6,441 workers across the globe.
How can I contact NOVOZYMES A/S/S?
NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]
MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)
MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
